Amplify Treatments, Testing and Advancements ETF (GERM)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Amplify Treatments, Testing and Advancements ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Amplify Treatments, Testing and Advancements ETF (GERM) has returned 0.00% so far this year and 0.00% over the past 12 months.

Based on dividend-adjusted daily data since Sep 6, 2024, GERM's average daily return is 0.00%, while the average monthly return is 0.00%.

Historically, 0% of months were positive and 100% were negative. The best month was Sep 2024 with a return of 0.0%, while the worst month was Sep 2024 at 0.0%. The longest winning streak lasted 0 consecutive months, and the longest losing streak was 0 months.

On a daily basis, GERM closed higher 0% of trading days. The best single day was Sep 9, 2024 with a return of 0.0%, while the worst single day was Sep 9, 2024 at 0.0%.

GERM has an expense ratio of 0.68%, placing it in the medium range.

The table below present risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Amplify Treatments, Testing and Advancements ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The portfolio has not yet recovered.

The chart below shows the rolling one-month volatility.